297. DESIGN OF A PHASE 3, POTENTIALLY PIVOTAL, INTERNATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL WITH EVENAMIDE, A GLUTAMATE MODULATOR, ADD-ON TO SGA IN PATIENTS WITH TREATMENT-RESISTANT SCHIZOPHRENIAPublished on 2025-08-184 months ago